

New Director Appointed

Genetic Signatures Limited (ASX: GSS, “**Genetic Signatures**” or the “**Company**”) is pleased to announce Dr Neil Gunn has been appointed to the Board of Directors. Dr Gunn was until recently President of Roche Sequencing Solutions, a Business Unit of Roche Diagnostics.

Dr Gunn has over 30 years of medical device and diagnostics experience from managing operations in both Europe and the USA. He has comprehensive knowledge of the diagnostic market, global product development, clinical, quality and regulatory processes, strategy development and commercial operations.

As head of Roche Sequencing Solutions (RSS) Dr Gunn oversaw all aspects of the business and managed a team of ~ 900 people. Prior to this he held the role of Vice President in Roche’s Molecular Diagnostic business unit. During this twelve-year tenure, he was responsible for over 120 diagnostic product launches (Instruments, assays, Software) with a principle focus on IVD clinical markets.

Commenting on his appointment, Dr Gunn said, “*Genetic Signatures has a unique technology in 3base™ that I believe will be a valuable addition to testing laboratories’ arsenal for diagnosing a broad range of infectious diseases. I look forward to contributing to the future success of the Company, particularly in North America and Europe*”.

Dr Nick Samaras, Genetic Signatures’ Chairman, said, “*Neil brings a great wealth of experience to Genetic Signatures and his considerable knowledge of the industry will help guide our Company through the next and most exciting phase of its evolution. The current SARS-CoV-2 pandemic has accelerated Genetic Signatures access to European and North American markets, and we can now take advantage of this opportunity and introduce the broader range of EasyScreen™ molecular diagnostic tests to customers*”.

For further information, see our website (www.geneticsignatures.com) or contact us as below:

Dr John Melki

Chief Executive Officer

john.melki@geneticsignatures.com

T: +61 (0)2 9870 7580

Peter Manley

Chief Financial Officer

peter.manley@geneticsignatures.com

Announcement authorised by Genetic Signatures’ Board of Directors

About Genetic Signatures Limited: Genetic Signatures is a specialist molecular diagnostics (MDx) company focused on the development and commercialisation of its proprietary platform technology, **3base™**. Genetic Signatures designs and manufactures a suite of real-time Polymerase Chain Reaction (PCR) based products for the routine detection of infectious diseases under the *EasyScreen™* brand. Genetic Signatures’ proprietary MDx **3base™** platform technology provides high-volume hospital and pathology laboratories the ability to screen for a wide array of infectious pathogens, with a high degree of specificity, in a rapid throughput (time-to-result) environment. Genetic Signatures’ current target markets are major hospital and pathology laboratories undertaking infectious disease screening.